Last active
May 9, 2022 14:39
-
-
Save afrendeiro/4aa133c2fcb5eb0152957b11ec753b74 to your computer and use it in GitHub Desktop.
Annotation of marker epitopes for various cell types
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
# This annotation of cell type markers is tailored for surface proteins | |
# normally profilid with multiplexed imaging (IMC, CODEX). | |
# It is a simple reference for myself and may be more detailed in some parts than others. | |
# This reference is hierarchical. | |
# This annotation is generally pan-tissue. | |
# Author: Andre Rendeiro | |
# License: CC BY-SA 2.0 | |
cell_types: | |
structural: | |
basal: | |
markers: | |
- KRT5 | |
- KRT14 | |
- p63 | |
- TP63 | |
- PDPN | |
epithelium: | |
markers: | |
- Cytokeratins | |
- Keratin818 | |
- K818 | |
# Lung: | |
club: | |
markers: | |
- KRT15 | |
- CD74 | |
- CC16 | |
- SCGB1A1 | |
hillock: | |
markers: | |
- KRT4 | |
- KRT13 | |
ciliated: | |
markers: | |
- FOXJ1 | |
- TUBB1 | |
- p73 | |
- TP73 | |
tuft: | |
markers: | |
- | |
goblet: | |
markers: | |
- MUC5A | |
- MUC5AC | |
- MUC5B | |
- SPDEF | |
aleveolar: | |
markers: | |
- CD44 | |
- Keratin818 | |
- K818 | |
typeI: | |
markers: | |
- SFTPB | |
- PDPN | |
- Keratin818 | |
- K818 | |
- AGER | |
- AQP5 | |
- PDPN | |
typeII: | |
markers: | |
- SFTPC | |
- SFTPA | |
- Keratin818 | |
- K818 | |
endothelial: | |
markers: | |
- EpCAM | |
- CD31 | |
- AQ1 | |
- Periostin | |
lymphatic: | |
markers: | |
- PDPN | |
mesenchymal: | |
markers: | |
- Vimentin | |
- VIM | |
fibroblast: | |
markers: | |
- AlphaSMA | |
- aSMA | |
- CollagenTypeI | |
- ColTypeI | |
cancer-associated fibroblast: | |
markers: | |
- | |
myofibroblast: | |
markers: | |
- ACTA2 | |
smooth_muscle: | |
markers: | |
- aSMA | |
- AlphaSMA | |
skeletal_muscle: | |
markers: | |
- CD56 | |
chondrocytes: | |
markers: | |
- SOX9 | |
immune: | |
lymphoid: | |
b_cell: | |
markers: | |
- CD45 | |
- CD20 | |
T_cell: | |
markers: | |
- CD45 | |
- CD3 | |
CD4: | |
markers: | |
- CD4 | |
Treg: | |
markers: | |
- FoxP3 | |
- FOXP3 | |
CD8: | |
markers: | |
- CD8a | |
- CD8A | |
NKcells: | |
markers: | |
- CD45 | |
- CD56 | |
- CD57 | |
- CD11b | |
- ITGAM | |
myeloid: | |
markers: | |
- CD45 | |
- CD16 | |
- CD68 | |
- CD11b | |
- CD11c | |
monocytes: | |
markers: | |
- CD14 | |
- IL1beta | |
- IL1B | |
macrophages: | |
markers: | |
- Vimentin | |
- VIM | |
- CD45 | |
- CD14 | |
- CD16 | |
- CD4 | |
- CD11b | |
- CD11c | |
- ITGAM | |
- CD163 | |
sources: | |
- https://www.cusabio.com/c-20938.html | |
M1: | |
phenotype: pro-inflamatory, autoimmune, obesity and diabetes, atherosclerosis | |
environment: virus, bacteria | |
differentiating_factors: | |
- LPS, TLR4, NFKB | |
- TLR4, NFKB | |
- IFNG, STAT1 | |
- IL6, STAT1 | |
markers: | |
- CD80 | |
- CD86 | |
- CD64 | |
- CD32 | |
- CD11c | |
M2: | |
phenotype: anti-inflamatory, wound healing, fibrosis, allergy and asthma | |
environment: cancer | |
differentiating_factors: | |
- IL6, STAT3 | |
- IL10, STAT3 | |
- IL4, STAT6 | |
- IL4, PI3K | |
- TGFBeta, SMAD3 | |
- IL13 | |
markers: | |
- CD206 | |
- CD68 | |
- CD163 | |
- ARG1 | |
neutrophils: | |
markers: | |
- CD11b | |
- CD11c | |
- CD15 | |
- MPO | |
- S100A9 | |
- S100A8 | |
- Periostin | |
dendritic_cells: | |
markers: | |
- CD45 | |
- CD14 | |
- CD16 | |
- FCGR3A | |
- Cd11c | |
- ITGAX | |
cDC1: | |
sources: | |
- https://doi.org/10.1016/j.smim.2021.101481 | |
functions: | |
- regulates host defense to viruses and other intracellular pathogens and promotes CD8+ T-cell-mediated anti-tumor immunity. | |
- promote tumor rejection given their specialization in recognition of dead and dying cells, cross-presentation and ability to drive CD8 + T-cell response. | |
markers: | |
- IRF8 | |
- BATF3 | |
- ID2 | |
- CLEC9A (DNGR-1) | |
- XCR1 | |
- BDCA-3 (CD141) | |
cDC2: | |
sources: | |
- https://doi.org/10.1016/j.smim.2021.101481 | |
functions: orchestrate host barrier protection as well as immunity to extracellular pathogens and/or allergens largely by promoting CD4+ helper T-cell responses through presentation of soluble antigens via MHC class II (MHC-II). | |
markers: | |
- IRF4 (high) | |
- RELB | |
- ZEB2 | |
- KLF4 | |
- NOTCH | |
pDC: | |
sources: | |
- https://doi.org/10.1016/j.smim.2021.101481 | |
functions: | |
- specialized for anti-viral responses and are an important source of IFN-I (and IFN-III) upon viral infection. | |
- pDC are considered to have a similar role in potentiating anti-tumoral immune responses via IFN-I production, however, pDC may also drive tolerance and immune suppression in the context of malignancy. | |
- While pDC are able to cross-present antigen to prime CD8 + T-cells, they exhibit inferior cross-presenting capacity relative to their conventional DC counterparts. | |
markers: | |
- CD11d | |
- BDCA-2 (CLEC4C or CD303) | |
- CD123 | |
- CD304 | |
- TCF4 | |
- IRF8 | |
- RUNX1 | |
tDC: | |
sources: 10.1016/j.celrep.2019.11.042 | |
comment: also known as AXL+ DC or ASDC | |
markers: | |
- AXL | |
MoDC: | |
sources: | |
- https://doi.org/10.1016/j.smim.2021.101481 | |
functions: | |
- highly context-dependent DC subset that differentiate in response to inflammatory stimuli and are recruited to sites of inflammation, including the TME, via the CCR2-CCL2 chemokine signaling axis. | |
- MoDC are heterogeneous and share substantial overlap with certain cDC2 subsets and monocytes, which is reflected in the diverse range of immune actions initiated by MoDC. | |
markers: | |
- CD14 | |
- CD88 | |
DC3: | |
sources: | |
- https://doi.org/10.1016/j.smim.2021.101481 | |
functions: | |
- tumor-infiltrating DCs. | |
- share overlapping phenotypic features with conventional DC, including both cDC1 and cDC2, yet harbor a distinct transcriptional profile. | |
- DC3 program is signified by the co-existence maturation/activation markers and an immunoregulatory profile that includes markers of DC migration, DC maturation, immune-regulation. | |
markers: | |
- | |
basophiles: | |
markers: | |
- | |
eosinophil: | |
markers: | |
- IL5RA | |
- CCR3 | |
- PRG2 | |
- PTGDR2 | |
- SIGLEC8 | |
- GATA2 | |
mast_cell: | |
markers: | |
- cKIT | |
- CD117 | |
- MastCellTryptase | |
- TPSAB1 | |
myeloid-derived suppressor cells: | |
markers: | |
- CD11b | |
- ITGAM | |
- GranzymeB | |
- GZMB | |
cell_states: | |
proliferative: | |
markers: | |
- Ki67 | |
- PCNA | |
- MCM2 | |
- pHH3 | |
cell death: | |
markers: | |
- CleavedCaspase3 | |
- CC3 | |
- CleavedPARP | |
- Survivin | |
- CitH3 | |
- SC5b9 | |
- iNOS | |
hypoxia: | |
markers: | |
- Carbonic anhydrase IX | |
cytotoxic: | |
markers: | |
- GranzymeB | |
activation: | |
markers: | |
- CD27 | |
- CD39 | |
- CD84 | |
# For DCs: | |
migration: | |
markers: | |
- CCR7 | |
- FSCN1 | |
maturation: | |
markers: | |
- LAMP3 | |
- CD80 | |
- CD83 | |
- CD40 | |
immune-regulation: | |
markers: | |
- PD-L1 | |
- PD-L2 | |
- IDO1 | |
- CD200 | |
inflammation: | |
markers: | |
- pSTAT3 | |
- pSTAT3Tyr705 | |
- pNFkbp65 | |
- IRF2BP2 | |
- IL6 | |
- IL1beta | |
- iNOS | |
arrest: | |
markers: | |
- p21 | |
- p27 | |
senescence: | |
markers: | |
- uPAR | |
- p21 | |
- p16 | |
- CDKN1A | |
- CDKN2A | |
infected: | |
markers: | |
- SARSSpikeS1 | |
# When updating, make sure syntax is correct: | |
# $ python -c "import yaml; yaml.safe_load(open('markers_to_cell_type_labels.yaml'))" |
Sign up for free
to join this conversation on GitHub.
Already have an account?
Sign in to comment